Recursion Pharmaceuticals

Primary contact

Recursion Pharmaceuticals combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, the company has broadened its platform to probe rich data from high-throughput automated screens for a number of indications — including aging, inflammation, infectious disease, oncology, and diagnostics. Recursion's ultimate vision is to leverage technology to build a robust and reliable map of human cellular biology, which would enable a radical shift in the pace and scale at which new treatments could benefit patients.
Primary contact

Funding 💰

Total $84.3M
Select investors Lux Capital, Felicis Ventures, Data Collective, Square 1 Bank, Advantage Capital, Epic Ventures, AME Cloud Ventures, Menlo Ventures, Obvious Ventures
Last update: May 8, 2018